Patents by Inventor Harald Jueppner
Harald Jueppner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9492508Abstract: Disclosed are two PTH analog ligands, SP-PTH-AAK and Aib-SP-PTH-AAK, that have long-acting activity at the PTH receptor, as demonstrated both in vitro and in vivo. These polypeptides are thus particularly useful in the treatment of diseases, such as hypoparathyroidism, in which long-acting activity is desired. The method of making the analog polypeptides is also disclosed.Type: GrantFiled: May 12, 2011Date of Patent: November 15, 2016Assignees: The General Hospital Corporation, Chugai Seiyaku Kabushiki KaishaInventors: Thomas J. Gardella, John T. Potts, Jr., Harald Jueppner, Makoto Okazaki
-
Patent number: 9377473Abstract: Immunoassays and methods for detecting and quantifying biological levels of intact fibroblast growth factor (FGF)-23, as well as the N-terminal and C-terminal fragments thereof in a biological sample. The relative amounts or ratios of FGF-23 relative the N-terminal and C-terminal fragments can also be determined. The systems and methods deploy antibodies that are specific to antigenic regions formed upon either the N-terminal or C-terminal regions of FGF-23 and are systematically applied such that intact FGF-23 and the fragments thereof can be detected and quantified. In certain embodiments, dissimilar labels conjugated to tracer antibodies or labeled antibodies specific to N-terminal and/or C-terminal tracer antibodies are utilized to facilitate detection and quantification of both whole length FGF-23 and any fragments thereof.Type: GrantFiled: March 15, 2013Date of Patent: June 28, 2016Inventor: Harald Jueppner
-
Patent number: 9057727Abstract: The present invention provides screening methods for GPCRs based on the discovery that the affinity of a receptor agonist for a GPCR (such as the parathyroid hormone receptor) when not bound to a G-protein is correlated with the length of time over which the agonist is effective, independently of its pharmacokinetic properties. The invention also provides PTH- and PTHrP-derived polypeptides.Type: GrantFiled: September 25, 2013Date of Patent: June 16, 2015Assignees: The General Hospital Corporation, Chugai Pharmaceutical Co., Ltd.Inventors: Thomas J. Gardella, John T. Potts, Jr., Masaru Shimizu, Fumihiko Ichikawa, Harald Jüppner, Makoto Okazaki
-
Publication number: 20140086842Abstract: The present invention provides screening methods for GPCRs based on the discovery that the affinity of a receptor agonist for a GPCR (such as the parathyroid hormone receptor) when not bound to a G-protein is correlated with the length of time over which the agonist is effective, independently of its pharmacokinetic properties. The invention also provides PTH- and PTHrP-derived polypeptides.Type: ApplicationFiled: September 25, 2013Publication date: March 27, 2014Applicants: Chugai Pharmaceutical Co., Ltd., The General Hospital CorporationInventors: Thomas J. GARDELLA, John T. Potts, JR., Masaru Shimizu, Fumihiko Ichikawa, Harald Jüppner, Makoto Okazaki
-
Patent number: 7985835Abstract: Novel parathyroid hormone peptide (PTH) and parathyroid hormone related peptide (PTHrP) or derivatives thereof which are biologically active are disclosed, as are pharmaceutical compositions containing such peptides, and synthetic and recombinant methods for producing such peptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing such peptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of such compounds.Type: GrantFiled: November 13, 2006Date of Patent: July 26, 2011Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Henry M. Kronenberg, John T. Potts, Harald Jüppner
-
Patent number: 7270968Abstract: The invention relates to a mammalian cell lacking type-1 parathyroid hormone (PTH)/parathyroid hormone-related peptide (PTHrP) receptor (PTH1R) activity and containing carboxyl-terminal parathyroid hormone receptor (CPTHR) activity. The invention also relates to a method of screening for agonists or antagonists for CPTHR.Type: GrantFiled: August 14, 2001Date of Patent: September 18, 2007Assignee: The General Hospital CorporationInventors: F. Richard Bringhurst, Paola Divieti, Harald Jüppner
-
Patent number: 7244834Abstract: Novel parathyroid hormone (PTH) peptides and analogs thereof of the PTH(1–34) fragment are disclosed that combine the N-terminal signaling domain (residues 1–9) and the C-terminal binding domain (residues 15–31) via a linker. Nucleic acid molecules and peptides for PTH(1–9)-(Gly)5-PTH(15–31) (PG5) and PTH(1–9)-(Gly)7-PTH(15–31) and a novel PTH receptor are disclosed. Additionally, methods of screening for PTH agonists, pharmaceutical compositions and methods of treatment are disclosed.Type: GrantFiled: March 3, 2006Date of Patent: July 17, 2007Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Henry M. Kronenberg, John T. Potts, Jr., Harald Jüppner
-
Patent number: 7153951Abstract: Novel parathyroid hormone peptide (PTH) and parathyroid hormone related peptide (PTHrP) or derivatives thereof which are biologically active are disclosed, as are pharmaceutical compositions containing such peptides, and synthetic and recombinant methods for producing such peptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing such peptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of such compounds.Type: GrantFiled: July 11, 2002Date of Patent: December 26, 2006Assignee: The General Hospital CorporationInventors: Thomas J Gardella, Henry M Kronenberg, John T Potts, Jr., Harald Jüppner
-
Patent number: 7094551Abstract: Immunoassays, assay methods, antibodies and methods of producing antibodies for the detection of fibroblast growth factor-23 (FGF-23). The immunoassay and assay method preferably comprise a non-competitive, sandwich-type assay utilizing a first bound antibody having affinity to a first site of the FGF-23 molecule, and a second, labeled antibody having an affinity for a second site present upon the FGF-23 molecule. The antibodies and methods of generating the same include administering antigenic peptide fragments of the FGF-23 molecule, monitoring the antibody titre produced thereby, extracting and selecting antibodies from the antisera having a specificity for the desired antigenic region of FGF-23, and purifying same. The antibodies may be incorporated into the immunoassay of the present invention or utilized for a variety of assay-type purposes for the detection of FGF-23.Type: GrantFiled: September 17, 2002Date of Patent: August 22, 2006Inventors: Richard J. Zahradnik, Jeffrey Lavigne, Harald Jueppner
-
Patent number: 7078487Abstract: The present invention relates to novel parathyroid hormone (PTH) and parathyroid hormone related protein (PTHrP) receptors (PTH1R and PTH3R) isolated from zebrafish. The receptors of the present invention share homology with previously identified parathyroid hormone (PTH)/parathyroid related protein (PTHrP) receptors. Isolated nucleic acid molecules are provided encoding the zebrafish PTH1R and PTH3R receptors. PTH1R and PTH3R receptor polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of PTH1R and PTH3R receptor activity and to diagnostic and therapeutic methods.Type: GrantFiled: February 25, 2003Date of Patent: July 18, 2006Assignee: The General Hospital CorporationInventors: Harald Jüppner, David A Rubin
-
Patent number: 7057012Abstract: Novel parathyroid hormone (PTH) peptides and analogs thereof of the PTH(1–34) fragment are disclosed that combine the N-terminal signaling domain (residues 1–9) and the C-terminal binding domain (residues 15–31) via a linker. Nucleic acid molecules and peptides for PTH(1–9)-(Gly)5-PTH(15–31) (PG5) and (1–9)-(Gly)7-PTH(15–31) and a novel PTH receptor are disclosed. Additionally, methods of screening for PTH agonists, pharmaceutical compositions and methods of treatment are disclosed.Type: GrantFiled: December 30, 1999Date of Patent: June 6, 2006Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Henry M. Kronenberg, John T. Potts, Jr., Harald Jüppner
-
Patent number: 7022815Abstract: Novel parathyroid hormone(PTH) polypeptide derivatives are disclosed, as are pharmaceutical compositions containing said polypeptides, and synthetic and recombinant methods for producing said polypeptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing said polypeptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of said compounds.Type: GrantFiled: September 29, 2000Date of Patent: April 4, 2006Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Henry M. Kronenberg, John T. Potts, Jr., Harald Jüppner
-
Publication number: 20050106755Abstract: Immunoassays, assay methods, antibodies and methods of producing antibodies for the detection of fibroblast growth factor-23 (FGF-23). The immunoassay and assay method preferably comprise a non-competitive, sandwich-type assay utilizing a first bound antibody having affinity to a first site of the FGF-23 molecule, and a second, labeled antibody having an affinity for a second site present upon the FGF-23 molecule. The antibodies and methods of generating the same include administering antigenic peptide fragments of the FGF-23 molecule, monitoring the antibody titre produced thereby, extracting and selecting antibodies from the antisera having a specificity for the desired antigenic region of FGF-23, and purifying same. The antibodies may be incorporated into the immunoassay of the present invention or utilized for a variety of assay-type purposes for the detection of FGF-23.Type: ApplicationFiled: September 17, 2002Publication date: May 19, 2005Inventors: Richard Zahradnik, Jeffrey Lavigne, Harald Jueppner
-
Patent number: 6541220Abstract: The present invention relates to novel parathyroid hormone (PTH) and parathyroid hormone related protein (PTHrP) receptors (PTH1R and PTH3R) isolated from zebrafish. The receptors of the present invention share homology with previously identified parathyroid hormone (PTH)/parathyroid related protein (PTHrP) receptors. Isolated nucleic acid molecules are provided encoding the zebrafish PTH1R and PTH3R receptors. PTH1R and PTH3R receptor polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of PTH1R and PTH3R receptor activity and to diagnostic and therapeutic methods.Type: GrantFiled: November 30, 1999Date of Patent: April 1, 2003Assignee: The General Hospital CorporationInventors: Harald Jüppner, David A. Rubin
-
Patent number: 6495662Abstract: Novel parathyroid hormone peptide (PTH) and parathyroid hormone related peptide (PTHrP) or derivatives thereof which are biologically active are disclosed, as are pharmaceutical compositions containing said peptides, and synthetic and recombinant methods for producing said peptides. Also disclosed are methods for treating mammalian conditions characterized by decreases in bone mass using therapeutically effective pharmaceutical compositions containing said peptides. Also disclosed are methods for screening candidate compounds of the invention for antagonistic or agonistic effects on parathyroid hormone receptor action. Also disclosed are diagnostic and therapeutic methods of said compounds.Type: GrantFiled: October 20, 1999Date of Patent: December 17, 2002Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Henry M. Kronenberg, John T. Potts, Jr., Harald Jüppner
-
Patent number: 6362163Abstract: The present invention relates to novel PTHrP analogs that have been converted into potent PTH-2 receptor agonists or antagonists by the substitution of one or more amino acid residues of PTHrP to the corresponding residue(s) of PTH. A method of treating various disease states associated with altered function of the PTH-2 receptor, using these PTHrP analogs, is also described.Type: GrantFiled: August 9, 2000Date of Patent: March 26, 2002Assignee: The General Hospital CorporationInventors: Thomas J. Gardella, Harald Jüppner